$7900 | Single User
$20500 | Global License

Hepatitis C: KOL Insight
[Lowest Price Guaranteed: $7,900]

Published by FirstWord Pharma: 01 Sep 2016 | 65295 | In Stock
Related Topics: Gas , Gastroenterology , Hepatology , Medical

Introduction

As hepatitis C cures multiply, how do experts evaluate the options?

Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus has shifted to cure, and physicians now have more treatment options than ever. But which ones should they use? Key opinion leaders provide their views, as well as give their candid insights on which regimens of the future could change treatment the HCV treatment paradigm again. Download sample pages now

Covering 7 currently marketed drugs and 6 pipeline therapies, this report reveals candid insights about the HCV landscape from 12 KOLs in North America and Europe. You’ll learn which treatments KOLs have confidence in, which ones they question – and which ones they think can challenge the standard of care in the future.

“Even with the new drugs coming into the market, Harvoni's eight-week treatment regimen is a strong argument for Gilead to keep it on the market ... I do not see Epclusa or Zepatier getting into that segment. The only other drug that can be a challenge to Harvoni is [ABT- 493/ABT-530], because they have eight-week results for every population so far."

US KOL

Take a tour of the report now:

The table of contents >

The key questions answered >

The key KOL quotes >

See the 13 therapies covered >

Find out who the 12 EU & US KOLs are >

Review an extract from the report - 1 drug profile >

Sample of brands covered:

Harvoni (sofosbuvir/ledipasvir; Gilead)

Sovaldi (sofosbuvir; Gilead)

Viekira Pak/Viekirax+Exviera (paritaprevir/ ombitasvir/ dasabuvir; AbbVie/Enanta)

Zepatier (elbasvir/grazoprevir; Merck & Co.)

Plus 9 more – download the full list now

Sample of KOLs interviewed

Adrian M. Di Bisceglie. Chief of Hepatology, Division of Gastroenterology and Hepatology, St. Louis University Liver Center, St. Louis, MO.

Eric Lawitz. Medical Director, Texas Liver Institute and Clinical Professor of Medicine, University of Texas Health Science Center, San Antonio, TX.

Geoffrey Dusheiko. Emeritus Professor of Medicine, Royal Free Hospital and University College School of Medicine, London, UK.

Peter Ferenci. Professor of Medicine, Medical University of Vienna, Vienna, Austria.

Plus 8 more – download the full list now

Top Takeaways

KOLs see room for improvement in streamlining the route to HCV cure. Do KOLs believe there is a future without ribavirin? What else is on their wish lists?

FDCs have challenged the utility of single-agent therapies. Do experts believe that monotherapies, including Sovaldi, Olysio and Daklinza, have a future role in treatment?

KOLs agree that governments’ good intentions to increase rates of HCV screening have had limited success. Beyond identifying more patients, where do KOLs see unmet needs in HCV?

Experts concur that existing drugs can successfully treat most patients with the common HCV genotypes. With little room for improving SVR rates, where do KOLs see the biggest opportunities for new entrants addressing these genotypes?

Pan-genotypic regimens stand to simplify the HCV treatment paradigm. Other than simplicity, what do KOLs expect from other pan-genotypic therapies in development?

Cost is the main factor determining the market availability of HCV drugs in many countries. How do KOLs feel about this?

Experts are intrigued by pipeline drugs targeting new pathways. Regulus Therapeutics’ RG-101 and Biotron’s BIT225 look interesting, but how do KOLs view their safety profile and market potential?

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.

You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Table of Contents
for Hepatitis C: KOL Insight

  • 1. Executive summary

    2. Research objectives

    3. Research focus

    3.1 HCV treatment landscape

    4. Marketed therapies

    4.1 Overview

    5. Protease inhibitors

    5.1 Overview

    5.1.1 Olysio (simeprevir; Janssen)

    6. NS5B polymerase inhibitors

    6.1 Sovaldi (sofosbuvir; Gilead Sciences)

    7. NS5A inhibitors

    7.1 Daklinza (daclatasvir; Bristol Myers Squibb)

    8. Fixed-dose combinations

    8.1 Epclusa (sofosbuvir/velpatasvir; Gilead Sciences)

    8.2 Harvoni (sofosbuvir/ledipasvir; Gilead Sciences)

    8.3 Viekira Pak/Viekirax+Exviera (paritaprevir/ombitasvir/dasabuvir; AbbVie/Enanta Pharmaceuticals)

    8.4 Zepatier (grazoprevir/elbasvir; Merck & Co.)

    9. Pipeline therapies

    9.1 Overview

    9.1.1 ABT-493/ABT-530 (AbbVie)

    9.1.2 Sofosbuvir/velpatasvir/GS-9857 (Gilead Sciences)

    9.1.3 Grazoprevir/MK-3682/MK-8408 (Merck & Co.)

    9.1.4 Odalasvir/AL-335/simeprevir (Janssen)

    9.1.5 BIT225 (Biotron)

    9.1.6 RG-101 (Regulus Therapeutics)

    10. Conclusion

    10.1 Current and future treatment algorithm

    11. Appendix

    11.1 KOL biographies

    11.1.1 KOLs from America

    11.1.2 KOLs from Europe

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

65295 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Hepatitis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Hepatitis C: Update Bulletin [February 2016]
IntroductionGain new KOL insights on the latest events that have the potential to shape the hepatiti...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Hepatitis C: KOL Insight
IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views: The hepatitis C pricing war - what impact on prescribers?
Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
29 Jan 2015 by FirstWord Pharma USD $695 More Info
Payer Insights: Hepatitis C
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
26 Sep 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?
Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
08 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?
Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
01 Apr 2014 by FirstWord Pharma USD $695 More Info
Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?
Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
01 Nov 2013 by FirstWord Pharma USD $695 More Info
Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Hepatitis C: KOL Insight | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...